CA2868998A1 - Novel epoprostenol formulation and method of making thereof - Google Patents

Novel epoprostenol formulation and method of making thereof Download PDF

Info

Publication number
CA2868998A1
CA2868998A1 CA2868998A CA2868998A CA2868998A1 CA 2868998 A1 CA2868998 A1 CA 2868998A1 CA 2868998 A CA2868998 A CA 2868998A CA 2868998 A CA2868998 A CA 2868998A CA 2868998 A1 CA2868998 A1 CA 2868998A1
Authority
CA
Canada
Prior art keywords
nil
epoprostenol
hrs
epp
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2868998A
Other languages
English (en)
French (fr)
Inventor
Nagesh R. Palepu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38345694&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2868998(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CA2868998A1 publication Critical patent/CA2868998A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2868998A 2006-02-03 2007-02-02 Novel epoprostenol formulation and method of making thereof Abandoned CA2868998A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US76476906P 2006-02-03 2006-02-03
US60/764,769 2006-02-03
US77256306P 2006-02-13 2006-02-13
US60/772,563 2006-02-13
US78342906P 2006-03-20 2006-03-20
US60/783,429 2006-03-20
CA2641393A CA2641393C (en) 2006-02-03 2007-02-02 Novel epoprostenol formulation and method of making thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2641393A Division CA2641393C (en) 2006-02-03 2007-02-02 Novel epoprostenol formulation and method of making thereof

Publications (1)

Publication Number Publication Date
CA2868998A1 true CA2868998A1 (en) 2007-08-16

Family

ID=38345694

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2868998A Abandoned CA2868998A1 (en) 2006-02-03 2007-02-02 Novel epoprostenol formulation and method of making thereof
CA2641393A Active CA2641393C (en) 2006-02-03 2007-02-02 Novel epoprostenol formulation and method of making thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2641393A Active CA2641393C (en) 2006-02-03 2007-02-02 Novel epoprostenol formulation and method of making thereof

Country Status (14)

Country Link
US (2) US8318802B2 (pt)
EP (1) EP1993557B1 (pt)
JP (1) JP5415771B2 (pt)
KR (1) KR101351668B1 (pt)
CN (1) CN101410119B (pt)
BR (1) BRPI0707488B8 (pt)
CA (2) CA2868998A1 (pt)
DK (1) DK1993557T3 (pt)
ES (1) ES2558705T3 (pt)
HU (1) HUE026166T2 (pt)
PL (1) PL1993557T3 (pt)
PT (1) PT1993557E (pt)
SI (1) SI1993557T1 (pt)
WO (1) WO2007092343A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2868998A1 (en) 2006-02-03 2007-08-16 Actelion Pharmaceuticals Ltd. Novel epoprostenol formulation and method of making thereof
CN101827612A (zh) 2007-09-07 2010-09-08 联合治疗公司 针对革兰氏阴性细菌具有选择性杀菌活性的缓冲液及其使用方法
BR112012002578B8 (pt) * 2009-08-07 2021-05-25 Scipharm Sarl usos de treprostinil ou de um derivado ou de um sal farmaceuticamente aceitável do mesmo para tratamento da fibrose cística
CN101669904B (zh) * 2009-09-29 2011-06-22 北京中海康医药科技发展有限公司 一种依前列醇脂质纳米粒及制备方法
US20120321728A1 (en) * 2011-06-15 2012-12-20 Ven Subbiah Nutritional formula for managing angina pectoris
JP5917034B2 (ja) * 2011-07-15 2016-05-11 ニプロ株式会社 カルシウムブロッカーを含有する固形医薬組成物
CN103585119A (zh) * 2013-11-13 2014-02-19 北京泰德制药股份有限公司 一种包含依前列醇及其药用盐的稳定化制剂及其制备方法
ITMI20142149A1 (it) * 2014-12-16 2016-06-16 L I A Di Giuseppe Capasso Apparato di diagnosi differenziale in medicina adattato per determinare la sequenza di test ottimale atta ad identificare una patologia secondo criteri di appropriatezza diagnostica
HU231031B1 (hu) * 2016-03-23 2019-12-30 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Megnövelt stabilitású epoprostenol nátrium és eljárás előállítására
US10912778B2 (en) 2016-12-14 2021-02-09 Respira Therapeutics, Inc. Methods for treatment of pulmonary hypertension
CN109330982A (zh) * 2018-09-13 2019-02-15 常州市第四制药厂有限公司 依前列醇冻干粉及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2021581B (en) 1978-05-17 1982-10-20 Wellcome Found Stabilisation of pgl derivatives
ZA787353B (en) * 1978-05-17 1980-08-27 Wellcome Found Pharmaceutical formulations
US7230014B1 (en) 1997-10-14 2007-06-12 Eisai Co., Ltd. Pharmaceutical formulation comprising glycine as a stabilizer
US6803386B2 (en) * 2002-01-16 2004-10-12 United Therapeutics Corporation Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer
DE10225551A1 (de) * 2002-06-06 2003-12-24 Schering Ag Verwendung von oral verfügbaren Prostacyclinderivaten für die Herstellung eines Arzneimittels zur Behandlung von Krankheiten, die mit Knochenmarködemen assoziiert sind
JP2007526329A (ja) 2004-03-04 2007-09-13 ワイス 賦形剤の結晶化を改善するための凍結乾燥法
CA2868998A1 (en) 2006-02-03 2007-08-16 Actelion Pharmaceuticals Ltd. Novel epoprostenol formulation and method of making thereof

Also Published As

Publication number Publication date
HUE026166T2 (en) 2016-05-30
CA2641393C (en) 2014-12-16
US8598227B2 (en) 2013-12-03
BRPI0707488B1 (pt) 2020-05-26
EP1993557A4 (en) 2012-07-25
US8318802B2 (en) 2012-11-27
KR101351668B1 (ko) 2014-01-14
ES2558705T3 (es) 2016-02-08
DK1993557T3 (en) 2015-12-07
BRPI0707488A2 (pt) 2011-05-03
WO2007092343A3 (en) 2008-01-17
CN101410119B (zh) 2012-03-07
JP2009525344A (ja) 2009-07-09
PT1993557E (pt) 2016-02-10
EP1993557A2 (en) 2008-11-26
US20090088468A1 (en) 2009-04-02
CA2641393A1 (en) 2007-08-16
BRPI0707488B8 (pt) 2021-05-25
CN101410119A (zh) 2009-04-15
WO2007092343A2 (en) 2007-08-16
PL1993557T3 (pl) 2016-05-31
KR20090004867A (ko) 2009-01-12
US20130018093A1 (en) 2013-01-17
JP5415771B2 (ja) 2014-02-12
SI1993557T1 (sl) 2016-01-29
EP1993557B1 (en) 2015-11-11

Similar Documents

Publication Publication Date Title
CA2641393C (en) Novel epoprostenol formulation and method of making thereof
NL193307C (nl) Bruispreparaat met analgetische werkzaamheid.
RU2345772C2 (ru) Лиофилизированные композиции cci-779
JP2021519764A (ja) 線維性疾患を処置する方法
CN115990138A (zh) 包含高纯度坎格雷洛的药物制剂以及制备和使用它们的方法
KR100700963B1 (ko) 켐토테신의 다당체 유도체를 함유하는 동결건조된 액상제제
JP3726255B2 (ja) 安定な凍結乾燥済みチオテパ組成物
EP1037652B1 (fr) Compositions pharmaceutiques a base de dalfopristine et de quinupristine et leur preparation
WO2008134630A1 (en) Dexrazoxane compounds for cardioprotection
JP2011137048A (ja) 新たな用途の薬学的調製物およびその調製物を製造するためのプロセス
KR100807650B1 (ko) Ｎ-[ｏ-(ｐ-피발로일옥시벤젠술포닐아미노)벤조일]글리신·모노나트륨염·4수화물의 동결 건조 제제 및 그 제조 방법
JP2002255814A (ja) アスピリンを含有する医薬組成物
RU2423130C2 (ru) Композиция, содержащая эпопростенол, и способ ее получения
CA2528899A1 (en) Flupirtin injectable galenic form
JP2023520543A (ja) 医薬製剤であるアドレノメデュリンのポリエチレングリコールベースのプロドラッグおよび使用
US6187746B1 (en) Pharmaceutical compositions based on dalfopristine and on quinupristine, and preparation thereof
US20130131089A1 (en) Dosage forms of elinogrel and methods of injectable administration thereof
WO2011137459A1 (en) Dosage forms of elinogrel and methods of injectable administration thereof
JPH1112194A (ja) 組織プラスミノーゲン活性化因子医薬組成物
KR20100059887A (ko) 동결 건조 제약 조성물
JPH06172181A (ja) 脈絡膜血流量増加剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141028

FZDE Discontinued

Effective date: 20170630